The estimated Net Worth of Pharma, Inc. Bridge Bio is at least $1.76 Million dollars as of 26 January 2021. Pharma Bio owns over 14,428,836 units of Eidos Therapeutics Inc stock worth over $122,210 and over the last 6 years Pharma sold EIDX stock worth over $1,637,473.
Sign up
Pharma Bio EIDX stock SEC Form 4 insiders trading
Pharma has made over 7 trades of the Eidos Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Pharma bought 14,428,836 units of EIDX stock worth $1,763,348,048 on 26 January 2021.
The largest trade Pharma's ever made was buying 14,428,836 units of Eidos Therapeutics Inc stock on 26 January 2021 worth over $1,763,348,048. On average, Pharma trades about 2,912,812 units every 136 days since 2018. As of 26 January 2021 Pharma still owns at least 1,000 units of Eidos Therapeutics Inc stock.
You can see the complete history of Pharma Bio stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharma Bio's mailing address?
Pharma's mailing address filed with the SEC is 421 KIPLING STREET, , PALO ALTO, CA, 94301.
Insiders trading at Eidos Therapeutics Inc
Over the last 6 years, insiders at Eidos Therapeutics Inc have traded over $18,169,563 worth of Eidos Therapeutics Inc stock and bought 30,345,136 units worth $349,599,962 . The most active insiders traders include Capital Management, L.P.Ra ..., Pharma, Inc. Bridge Bio und Rajeev M. Shah. On average, Eidos Therapeutics Inc executives and independent directors trade stock every 13 days with the average trade being worth of $52,576,942. The most recent stock trade was executed by Pharma, Inc. Bridge Bio on 26 January 2021, trading 14,428,836 units of EIDX stock currently worth $1,763,348,048.
What does Eidos Therapeutics Inc's logo look like?
Complete history of Pharma Bio stock trades at Eidos Therapeutics Inc
Eidos Therapeutics Inc executives and stock owners
Eidos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Cameron Turtle,
Chief Business Officer -
William Lis,
Independent Director -
Uma Sinha,
Chief Scientific Officer, Director -
Ali Satvat,
Independent Director -
Neil Kumar,
Chief Executive Officer, Director -
Douglas Rohlen,
Independent Director -
Suzanne Hooper,
Independent Director -
Jonathan Fox,
President, Chief Medical Officer -
Franco Valle,
Senior Vice President, Finance -
Rajeev M. Shah,
Director -
Capital Management, L.P.Ra ...,
-
Christine Siu,
CFO and Secretary -
Hoyoung Huh,
Director -
Pharma, Inc. Bridge Bio,
10% owner -
Eric Aguiar,
Director